Open access
Sep 2026
Fibronectin inhibition restores myelination in endothelial TNFR2-dependent nonremitting experimental autoimmune encephalomyelitis.
Therapeutically, systemic fibronectin inhibition restored regeneration and clinical remission, as well as prevented OPC accumulation at lesions, providing strong preclinical evidence for fibronectin-targeting therapies in MS and other demyelinating disorders.
Aikaterini Nanou, Konstantinos Apostolou-Karampelis, V. Triantafyllidou et al.
· Proceedings of the National... · 0 citations